RT Journal Article
SR Electronic
T1 Who is at risk of poor mental health following COVID-19 outpatient management?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.22.21263949
DO 10.1101/2021.09.22.21263949
A1 Hüfner, Katharina
A1 Tymoszuk, Piotr
A1 Ausserhofer, Dietmar
A1 Sahanic, Sabina
A1 Pizzini, Alex
A1 Rass, Verena
A1 Galffy, Matyas
A1 Böhm, Anna
A1 Kurz, Katharina
A1 Sonnweber, Thomas
A1 Tancevski, Ivan
A1 Kiechl, Stefan
A1 Huber, Andreas
A1 Plagg, Barbara
A1 Wiedermann, Christian
A1 Bellmann-Weiler, Rosa
A1 Bachler, Herbert
A1 Weiss, Günter
A1 Piccoliori, Giuliano
A1 Helbok, Raimund
A1 Löffler-Ragg, Judith
A1 Sperner-Unterweger, Barbara
YR 2021
UL http://medrxiv.org/content/early/2021/09/26/2021.09.22.21263949.abstract
AB Background COVID-19 convalescents are at risk of developing a de novo mental health disorder or of worsening of a pre-existing one. The objectives of our study was to phenotype individuals at highest risk of mental health disorders among COVID-19 outpatients.Methods We conducted a binational online survey study with adult non-hospitalized COVID-19 convalescents (Austria/AT: n=1157, Italy/IT: n= 893). Primary endpoints were positive screening for depression and anxiety (PHQ-4, Patient Health Questionnaire) and self-perceived overall mental health and quality of life rated with 4 point Likert scales. Psychosocial stress was surveyed with a modified PHQ stress module. Associations of the mental health with socio-demographic variables, COVID-19 course and recovery data were assessed by multi-parameter random forest and serial univariable modeling. Mental disorder risk subsets were defined by self-organizing map and hierarchical clustering algorithms. The survey analyses are publicly available (https://im2-ibk.shinyapps.io/mental_health_dashboard/).Results In the study cohorts, 4.6 (IT)/6% (AT) of participants reported depression and/or anxiety before to infection. At a median of 79 days (AT)/96 days (IT) post COVID-19 onset, 12.4 (AT)/19.3% (IT) of subjects were screened positive for anxiety and 17.3 (AT)/23.2% (IT) for depression. Over one-fifth of the respondents rated their overall mental health (AT: 21.8%, IT: 24.1%) or quality of life (AT: 20.3%, IT: 25.9%) as fair or poor. In both study collectives, psychosocial stress, high numbers of acute and persistent COVID-19 complaints and the presence of acute neurocognitive symptoms (impaired concentration, confusion, forgetfulness) were the strongest correlates of deteriorating mental health and poor quality of life. In clustering analysis, these variables defined a ‘high risk’ subset with particularly high propensity of post-COVID-19 mental health impairment and decreased quality of life. Pre-existing depression or anxiety was associated with an increased symptom burden during acute COVID-19 and recovery.Conclusion Our study revealed a bidirectional relationship between COVID-19 symptoms and mental health. We put forward specific acute symptoms of the disease as ‘red flags’ of mental health deterioration which should prompt general practitioners to identify COVID-19 patients who may benefit from early psychological and psychiatric intervention.Trial registration ClinicalTrials.gov: NCT04661462.Competing Interest StatementPT owns his data science enterprise, Data Analytics as a Service Tirol. PT has also received an honorarium for the study data management, curation and analysis and minor manuscript work. The author has no other competing interests to declare. Other authors have no competing interests to declare.Clinical TrialNCT04661462Funding StatementThe study was funded by the Research Fund of the State of Tyrol, Austria (Project GZ 71934, JLR)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Each participant gave a digitally signed informed consent to participate. The study protocol was approved by the institutional review boards of the Medical University of Innsbruck (AT, approval number: 1257/2020) and of the Autonomous Province of Bolzano - South Tyrol (IT: 0150701).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Analysis of the psychosocial features is available as an online dashboard (https://im2-ibk.shinyapps.io/mental_health_dashboard). The complete R analysis pipeline is available at https://github.com/PiotrTymoszuk/mental-health-after-COVID-19.